Journal of Cancer Research and Clinical Oncology

, Volume 145, Issue 9, pp 2383–2396 | Cite as

Co-expression network analysis identified candidate biomarkers in association with progression and prognosis of breast cancer

  • Qiang Zhou
  • Jiangbo Ren
  • Jinxuan Hou
  • Gang Wang
  • Lingao Ju
  • Yu XiaoEmail author
  • Yan GongEmail author
Original Article – Clinical Oncology



Breast cancer is one of the most common malignancies among females, and its prognosis is affected by a complex network of gene interactions. Weighted gene co-expression network analysis was used to construct free-scale gene co-expression networks and to identify potential biomarkers for breast cancer progression.


The gene expression profiles of GSE42568 were downloaded from the Gene Expression Omnibus database. RNA-sequencing data and clinical information of breast cancer from TCGA were used for validation.


A total of ten modules were established by the average linkage hierarchical clustering. We identified 58 network hub genes in the significant module (R2 = 0.44) and 6 hub genes (AGO2, CDC20, CDCA5, MCM10, MYBL2, and TTK), which were significantly correlated with prognosis. Receiver-operating characteristic curve validated that the mRNA levels of these six genes exhibited excellent diagnostic efficiency in the test data set of GSE42568. RNA-sequencing data from TCGA showed that the expression levels of these six genes were higher in triple-negative tumors. One-way ANOVA suggested that these six genes were upregulated at more advanced stages. The results of independent sample t test indicated that MCM10 and TTK were associated with tumor size, and that AGO2, CDC20, CDCA5, MCM10, and MYBL2 were overexpressed in lymph-node positive breast cancer.


AGO2, CDC20, CDCA5, MCM10, MYBL2, and TTK were identified as candidate biomarkers for further basic and clinical research on breast cancer based on co-expression analysis.


Breast cancer Weighted gene co-expression network analysis Prognosis Gene Expression Omnibus Biomarker 



The excellent technical assistance of Jianing Tang is gratefully acknowledged.


This study was supported by National Natural Science Foundation of China (Grant No. 81800429), the Fundamental Research Funds for the Central Universities (Grant No. 2042018kf0065), Health Commission of Hubei Province Scientific Research Project (Grant No. WJ2019Q047), and Zhongnan Hospital of Wuhan University Science, Technology and Innovation Seed Fund (Grant Nos. znpy2017001 and znpy2018028).

Compliance with ethical standards

Conflict of interest

The authors declare no conflicts of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Supplementary material

432_2019_2974_MOESM1_ESM.docx (3.9 mb)
Supplementary material 1 (DOCX 3965 kb)


  1. Adams BD, Claffey KP, White BA (2009) Argonaute-2 expression is regulated by epidermal growth factor receptor and mitogen-activated protein kinase signaling and correlates with a transformed phenotype in breast cancer cells. Endocrinology 150:14–23. CrossRefPubMedGoogle Scholar
  2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. CrossRefPubMedGoogle Scholar
  3. Chang IW et al (2015) CDCA5 overexpression is an indicator of poor prognosis in patients with urothelial carcinomas of the upper urinary tract and urinary bladder. Am J Transl Res 7:710–722PubMedPubMedCentralGoogle Scholar
  4. Chen T et al (2017) Role of triosephosphate isomerase and downstream functional genes on gastric cancer. Oncol Rep 38:1822–1832. CrossRefPubMedGoogle Scholar
  5. Chen X et al (2018) A novel USP9X substrate TTK contributes to tumorigenesis in non-small-cell lung cancer. Theranostics 8:2348–2360. CrossRefPubMedPubMedCentralGoogle Scholar
  6. da Huang W, Sherman BT, Lempicki RA (2009a) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37:1–13. CrossRefGoogle Scholar
  7. da Huang W, Sherman BT, Lempicki RA (2009b) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4:44–57. CrossRefGoogle Scholar
  8. Fan X et al (2018) B-Myb mediates proliferation and migration of non-small-cell lung cancer via suppressing IGFBP3. Int J Mol Sci. CrossRefPubMedPubMedCentralGoogle Scholar
  9. Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N (2001) Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol 28:400–418CrossRefPubMedGoogle Scholar
  10. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE (1994) Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet (Lond, Engl) 343:692–695CrossRefGoogle Scholar
  11. Gao Y, Zhang B, Wang Y, Shang G (2018) Cdc20 inhibitor apcin inhibits the growth and invasion of osteosarcoma cells. Oncol Rep 40:841–848. CrossRefPubMedGoogle Scholar
  12. Gonzalez-Angulo AM et al (2011) Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 17:1082–1089. CrossRefPubMedPubMedCentralGoogle Scholar
  13. Guan Z, Cheng W, Huang D, Wei A (2018) High MYBL2 expression and transcription regulatory activity is associated with poor overall survival in patients with hepatocellular carcinoma. Curr Res Transl Med 66:27–32. CrossRefPubMedGoogle Scholar
  14. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z (2010) An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1809 patients. Breast Cancer Res Treat 123:725–731. CrossRefPubMedGoogle Scholar
  15. Jung KH et al (2018) Adjuvant subcutaneous trastuzumab for HER2-positive early breast cancer: subgroup analyses of safety and active medical conditions by body weight in the SafeHer phase III study. The oncologist 23:1137–1143. CrossRefPubMedPubMedCentralGoogle Scholar
  16. Kang G et al (2013) Exome sequencing identifies early gastric carcinoma as an early stage of advanced gastric cancer. PloS One 8:e82770. CrossRefPubMedPubMedCentralGoogle Scholar
  17. Khalil MY, Grandis JR, Shin DM (2003) Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer. Expert Rev Anticancer Ther 3:367–380. CrossRefPubMedGoogle Scholar
  18. King CR, Kraus MH, Aaronson SA (1985) Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science (New York) 229:974–976CrossRefGoogle Scholar
  19. Landi MT et al (2008) Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PloS One 3:e1651. CrossRefPubMedPubMedCentralGoogle Scholar
  20. Langfelder P, Horvath S (2008) WGCNA: an R package for weighted correlation network analysis. BMC Bioinform 9:559. CrossRefGoogle Scholar
  21. Li WM et al (2016) MCM10 overexpression implicates adverse prognosis in urothelial carcinoma. Oncotarget 7:77777–77792. CrossRefPubMedPubMedCentralGoogle Scholar
  22. Lin D et al (1994) Constitutive expression of B-myb can bypass p53-induced Waf1/Cip1-mediated G1 arrest. Proc Natl Acad Sci USA 91:10079–10083CrossRefPubMedGoogle Scholar
  23. Lu P et al (2014) Genome-wide gene expression profile analyses identify CTTN as a potential prognostic marker in esophageal cancer. PloS One 9:e88918. CrossRefPubMedPubMedCentralGoogle Scholar
  24. Mahadevappa R et al (2018) DNA replication licensing protein MCM10 promotes tumor progression and is a novel prognostic biomarker and potential therapeutic target in breast cancer. Cancers. CrossRefPubMedPubMedCentralGoogle Scholar
  25. Mannefeld M, Klassen E, Gaubatz S (2009) B-MYB is required for recovery from the DNA damage-induced G2 checkpoint in p53 mutant cells. Cancer Res 69:4073–4080. CrossRefPubMedGoogle Scholar
  26. Musa J, Aynaud MM, Mirabeau O, Delattre O, Grunewald TG (2017) MYBL2 (B-Myb): a central regulator of cell proliferation, cell survival and differentiation involved in tumorigenesis. Cell Death Dis 8:e2895. CrossRefPubMedPubMedCentralGoogle Scholar
  27. O’Shaughnessy J (2005) Extending survival with chemotherapy in metastatic breast cancer. Oncologist 10(Suppl 3):20–29. CrossRefPubMedGoogle Scholar
  28. Paterson MC et al (1991) Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res 51:556–567PubMedGoogle Scholar
  29. Paul D, Ghorai S, Dinesh US, Shetty P, Chattopadhyay S, Santra MK (2017) Cdc20 directs proteasome-mediated degradation of the tumor suppressor SMAR1 in higher grades of cancer through the anaphase promoting complex. Cell Death Dis 8:e2882. CrossRefPubMedPubMedCentralGoogle Scholar
  30. Peng YP et al (2016) The expression and prognostic roles of MCMs in pancreatic cancer. PloS One 11:e0164150. CrossRefPubMedPubMedCentralGoogle Scholar
  31. Press MF et al (1997) HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 15:2894–2904. CrossRefPubMedGoogle Scholar
  32. Redig AJ, McAllister SS (2013) Breast cancer as a systemic disease: a view of metastasis. J Intern Med 274:113–126. CrossRefPubMedPubMedCentralGoogle Scholar
  33. Ren F et al (2015) MYBL2 is an independent prognostic marker that has tumor-promoting functions in colorectal cancer. Am J Cancer Res 5:1542–1552PubMedPubMedCentralGoogle Scholar
  34. Rimawi M et al (2018) First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized open-label phase II trial. J Clin Oncol 36:2826–2835. CrossRefPubMedGoogle Scholar
  35. Sagara Y et al (2018) Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03. Breast Cancer Res Treat 171:675–683. CrossRefPubMedGoogle Scholar
  36. Sala A (2005) B-MYB, a transcription factor implicated in regulating cell cycle, apoptosis and cancer. Eur J Cancer (Oxford, England: 1990) 41:2479–2484. CrossRefGoogle Scholar
  37. Shen Z et al (2018) CDCA5 regulates proliferation in hepatocellular carcinoma and has potential as a negative prognostic marker. OncoTargets Ther 11:891–901. CrossRefGoogle Scholar
  38. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (New York) 235:177–182CrossRefGoogle Scholar
  39. Takada M et al (2018) Prediction of postoperative disease-free survival and brain metastasis for HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab using a machine learning algorithm. Breast Cancer Res Treat. CrossRefPubMedGoogle Scholar
  40. Tao D, Pan Y, Jiang G, Lu H, Zheng S, Lin H, Cao F (2015) B-Myb regulates snail expression to promote epithelial-to-mesenchymal transition and invasion of breast cancer cell. Med Oncol (Northwood, London, England) 32:412. CrossRefGoogle Scholar
  41. Thorner AR, Hoadley KA, Parker JS, Winkel S, Millikan RC, Perou CM (2009) In vitro and in vivo analysis of B-Myb in basal-like breast cancer. Oncogene 28:742–751. CrossRefPubMedGoogle Scholar
  42. Thu KL et al (2018) Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer. Proc Natl Acad Sci USA 115:E1570–e1577. CrossRefPubMedGoogle Scholar
  43. Trainer AH, Thompson E, James PA (2011) BRCA and beyond: a genome-first approach to familial breast cancer risk assessment. Discov Med 12:433–443PubMedGoogle Scholar
  44. Uhlen M et al (2010) Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 28:1248–1250. CrossRefPubMedGoogle Scholar
  45. Uhlen M et al (2015) Proteomics. Tissue-based map of the human proteome. Science (New York) 347:1260419. CrossRefGoogle Scholar
  46. von Minckwitz G et al (2018) Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial. Lancet Oncol 19:987–998. CrossRefGoogle Scholar
  47. Wang J et al (2017) Cdc20 overexpression is involved in temozolomide-resistant glioma cells with epithelial-mesenchymal transition. Cell Cycle (Georget) 16:2355–2365. CrossRefGoogle Scholar
  48. Wang J et al (2018) Silencing of CDCA5 inhibits cancer progression and serves as a prognostic biomarker for hepatocellular carcinoma. Oncol Rep 40:1875–1884. CrossRefPubMedPubMedCentralGoogle Scholar
  49. Yuan B et al (2006) Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability. Clin Cancer Res 12:405–410. CrossRefPubMedGoogle Scholar
  50. Zhang H et al (2018a) Acetylation of AGO2 promotes cancer progression by increasing oncogenic miR-19b biogenesis. Oncogene. CrossRefPubMedPubMedCentralGoogle Scholar
  51. Zhang Z, Shen M, Zhou G (2018b) Upregulation of CDCA5 promotes gastric cancer malignant progression via influencing cyclin E1. Biochem Biophys Res Commun 496:482–489. CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of UrologyZhongnan Hospital of Wuhan UniversityWuhanChina
  2. 2.Department of Biological RepositoriesZhongnan Hospital of Wuhan UniversityWuhanChina
  3. 3.Department of Thyroid and Breast SurgeryZhongnan Hospital of Wuhan UniversityWuhanChina
  4. 4.Human Genetics Resource Preservation Center of Hubei ProvinceZhongnan Hospital of Wuhan UniversityWuhanChina
  5. 5.Laboratory of Precision MedicineZhongnan Hospital of Wuhan UniversityWuhanChina

Personalised recommendations